The European Commission has granted approval for Amgen’s UPLIZNA® (inebilizumab) as an add-on treatment for adults with generalized myasthenia gravis making it the first and only CD19-targeted therapy authorized in Europe for this rare, debilitating autoimmune muscle disease. The approval is backed by pivotal Phase 3 data from the landmark MINT trial.
Groundbreaking data from the KALOS and LOGOS trials reveal that Breztri (BGF) triple-therapy significantly outperforms standard dual-combination inhalers for uncontrolled asthma. Published in The Lancet Respiratory Medicine, the study confirms a 76mL improvement in lung function and a meaningful reduction in severe exacerbations, signaling a potential shift in the global standard of care.
Final data from the Phase III ALIGN study reveals that Vanrafia® (atrasentan) effectively slows eGFR decline in IgAN patients, even when combined with SGLT2 inhibitors. Novartis moves toward traditional regulatory approval in 2026.
Avantor, Inc. concludes fiscal 2025 with a strategic pivot. While facing a GAAP net loss due to significant impairment charges, CEO Emmanuel Ligner introduces the “Revival” initiative a comprehensive plan to modernize e-commerce, relaunch the VWR brand, and optimize go-to-market strategies for a “transition year” in 2026.
Eli Lilly has entered a $2.4 billion definitive agreement to acquire Orna Therapeutics. This strategic move integrates Orna’s proprietary circular RNA platform and in vivo CAR-T pipeline into Lilly’s growing portfolio, signaling a major shift toward more accessible and scalable genetic medicines for B cell-driven autoimmune diseases.
AstraZeneca (AZN) capped off 2025 with a powerhouse performance, reaching $58.74 billion in total revenue and expanding its portfolio to 16 blockbuster drugs. With 100+ Phase III trials ongoing, CEO Pascal Soriot reaffirmed the company’s path to an $80 billion revenue target by 2030.
Following the release of its IQVIA 2025 earnings, the life sciences leader reported a record-breaking $32.7 billion backlog and a double-digit revenue surge in the fourth quarter, outperforming Wall Street expectations. As the company transitions into 2026, it is doubling down on a specialized Healthcare-grade AI strategy—anchored by its proprietary Med-R1 reasoning model and strategic cloud partnerships with NVIDIA and AWS—to safeguard its core business against industry-wide disruption.
Pfizer has reached a major regulatory milestone with the FDA granting Priority Review for HYMPAVZI™ (marstacimab) to include children as young as six and patients with hemophilia inhibitors. If approved, HYMPAVZI would become the first non-factor prophylactic treatment for children aged 6–11 with hemophilia B, offering a simplified, once-weekly injection that addresses a massive unmet medical need in the rare disease community.
Amgen closes 2025 with record revenues of $36.8 billion, driven by double-digit volume growth. Looking ahead to 2026, the biotech giant focuses on the global commercialization of Imdelltra and high-stakes data readouts for its obesity candidate, MariTide.
Eli Lilly (LLY) shattered Q4 2025 expectations with $19.3 billion in revenue, marking a 43% year-over-year increase. Driven by the explosive demand for weight-loss treatments Mounjaro and Zepbound, the pharmaceutical giant issued a confident 2026 revenue guidance of $80B–$83B, signaling continued dominance in the metabolic health market.
